JYNT · JOINT Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. The Joint Corp. reported Q2 2026 revenue growth of 14% to $15.2M and a $1.4M increase in Adjusted EBITDA from continuing operations to $1.5M as refranchising nears completion, while system-wide sales declined 3.7% to $180.0M and comp sales were (2.8)%. The company reiterated full-year 2026 guidance for system-wide sales, comps, and Adjusted EBITDA, but lowered new franchised clinic openings to 22-26 from prior 30-35.
- + Revenue grew 14% year-over-year to $15.2M, reflecting the shift to the pure-play franchisor revenue model
- + Adjusted EBITDA from continuing operations rose by $1.4M to $1.5M, underscoring operating leverage in the new franchisor model
- + Cash flow from operating activities grew 152% to $2.2M, driving free cash flow of $1.9M (+$1.6M YoY)
- + Refranchising substantially complete, positioning the company as a capital-light, pure-play franchisor
- + Disciplined capital allocation with $677K in share repurchases and three RD territory buybacks in the quarter
- − System-wide sales declined 3.7% to $180.0M year-over-year
- − Comp sales remained negative at (2.8)% in Q2 2026
- − New franchised clinic openings guidance lowered to 22-26 from prior 30-35
- − Selling and marketing expenses surged 40% year-over-year to $4.9M
- − Net loss from continuing operations of $251K and clinic count net decline expected for 2026
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $1,452,625 | Three Months Ended June 30, 2026 filing | -55.2% |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net (loss) income $653,021
-$126,439 Net interest income
+$424,551 Depreciation and amortization expense
+$6,549 Income tax expense (benefit)
+$423,180 Stock-based compensation expense
+$332,005 Acquisition-related expenses
+$1,024,559 Net loss on disposition or impairment
+$89,029 Restructuring costs
+$333,698 Litigation expenses
= Adjusted EBITDA $3,160,153
|
|||
| Comp sales of clinics that have been open for at least 13 full months | 2.8% | the three months ended June 30, 2026 filing | — |
| Franchise licenses sold | 10 | the three months ended June 30, 2026 filing | — |
| System-wide sales for all clinics open for any amount of time | $128M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA from consolidated operations non-GAAP | $3.2M | Q2 2026 | — |
| Adjusted EBITDA from continuing operations non-GAAP | $1.5M | Q2 2026 | — |
| Cash flow from operating activities | $2.2M | Q2 2026 | — |
| Clinics refranchised | 29 | Q2 2026 | — |
| Comp sales | -2.8% | Q2 2026 | — |
| Company-owned or managed clinics | 45 | as of June 30, 2026 | — |
| Franchised clinics | 896 | as of June 30, 2026 | — |
| Free cash flow non-GAAP | $225,192 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Shares repurchased | 82,000 | Q2 2026 | — |
| Total clinic count | 941 | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JYNT
this stock
JOINT Corp
|
$100.70M | -18.3% | +16.2% | 26.4 | 3.1% |
|
HCA
HCA Healthcare, Inc.
|
$98.72B | -4.7% | +7.1% | 15.3 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$26.27B | -18.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.98B | +31.1% | +0.9% | 10.1 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.10B | +15.5% | +10.5% | 20.0 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JYNT | -4.7% | -11.3% | -22.8% | -3.8% | -18.4% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -6.0% | -13.5% | -31.8% | -5.3% | -31.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.